The organization of a Zn-based metal–organic framework (MOF) as the first solvent switching catalyst has been achieved via in situ ligand incorporation.
No takes yet. Share an insight, caveat, or question.
Rouhani et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: